The cost of metastatic colorectal cancer patients with brafv600e mutations in greece
Value in Health(2022)
Abstract
Tumor harboring BRAFV600E mutation are among the most aggressive forms of metastatic colorectal cancer (mCRC), with an estimated incidence of 8-12% of mCRC cases in Europe. The aim of this study is to explore the treatment strategy and economic burden of mCRC patients with BRAFV600E mutation in Greece.
MoreTranslated text
Key words
brafv600e mutations,metastatic colorectal cancer patients,metastatic colorectal cancer,colorectal cancer,cost
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined